![](/wp-content/uploads/2018/10/Rk4NHzFLQdK8fd9pJMRr.png)
$599
Merck Q4 ’16 Earnings Update
Merck hosted their Q4 and full-year 2016 earnings update today. Overall, there was minimal diabetes-related discussion as the primary focus was on Keytruda.
Merck hosted their Q4 and full-year 2016 earnings update today. Overall, there was minimal diabetes-related discussion as the primary focus was on Keytruda.